Fit For ATMPs? Creating an EU Regulatory Framework that Works for Transformative Therapies

Hosted by the MEP Interest Group for Transformative Therapies (TRANSFORM)

15:00 - 17:00

This meeting will bring together policy-makers (MEPs, representatives of EU institutions, national representatives), regulators (EMA), patient representatives, medical experts, scientists, researchers, industry representatives and academics to discuss recommended changes in policy and practice, and offer solutions to ensure a regulatory framework that is fit-for purpose for ATMPs and has patient safety at its centre.

The discussion will focus on legislative dossiers that touch on the ATMP regulatory framework, namely the review of the Blood, Tissues and Cells legislation (expected mid-July) and the General Pharmaceutical legislation.

A recording will be made available after the event.

Confirmed Speakers

@TRANSFORM_CGT on Twitter Follow us →

Interesting event @alliancerm today! With the EU Pharma legislation review, the new HTA Regulation and the EHDS, the EU has an opportunity to encourage innovation & ensure that ATMPs are a central part of the EU’s healthcare landscape @Kympouropoulos @susanasolisp #MEPsforATMPs https://t.co/ODkSdMePW9
29 November at 9:07pm
MEP @dieGamon endorses Recommendation 7️⃣ of the TRANSFORM MEP Charter, which calls for improved infrastructure and cross-border healthcare for ATMPs #MEPsforATMPs https://t.co/nDDxEhvqrr
22 November at 11:33am
Hear MEP @susanasolis outline Recommendation 6️⃣ of the TRANSFORM MEP Charter. Considering innovative access pathways for cell and gene therapies could help bring more ATMPs to #patients #MEPsforATMPs https://t.co/R8cs4snLL9
17 November at 10:25am